The ANGEL-MS extension study will offer the 260 patients enrolled in the on-going Phase IIb CHANGE-MS study the opportunity to continue their treatment for an additional two years and will provide additional efficacy and tolerance data.

Geneuro, Switzerland and Servier, France, 7 December 2016 : GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis, and Servier, a leading independent international pharmaceutical company, announce the setting-up of ANGEL-MS, a long-term extension study for patients with multiple sclerosis (MS) and treated with GNbAC1.

More information at :